Generex Posts Slides, Script & Recording of Investor Conference Call
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (“Generex”) announces that the company has posted the slides and the transcript of the December 3, 2018 investor conference call on the company website in the Investors section at https://www.generex.com/investor.
“We would like to thank our investors and other interested parties for participating in the Generex investor conference call yesterday,” said Joe Moscato, Generex CEO. “Following our presentations, I trust that the investment community has a better appreciation of our vision and strategic plan to build Generex into a next generation, integrated healthcare holding company. As discussed on the call, Generex is focused on generating revenue and operating capital through NuGenerex Distribution Solutions (NDS) that has been created by our acquisition of a management services organization (MSO), a network of pharmacies, a clinical laboratory, and a DME company, DME-IQ. We plan to expand our MSO network services in up to 27 states where we are working to contract and/or purchase ancillary service providers for pharmacy, laboratories, and DME, and we are partnering with physicians in those states to promote patient centric care. We also plan to add a significant acquisition to our network that includes a nation-wide direct to patient pharmacy business, offering significant revenues and enabling a rapid growth trajectory for NDS.”
Mr. Moscato continued, “In addition to our MSO and pharmacy acquisitions, we have acquired two exciting companies in the wound care & regenerative medicine space, Regentys and Olaregen, and will be launching Excellagen®, our first product from Olaregen in early 2019. Excellagen® is FDA cleared for the treatment of 17 wound care indications, including surgical incisions, diabetic ulcers and pressure ulcers (bed sores), trauma wounds and burns, among others in the $20 billion wound care market. It is exciting that Generex, led by the experienced commercial team at Olaregen, will be launching our first drug through our MSO and pharmacy networks in the highly valuable wound care market in 2019, and we look forward to reporting on our commercial results with Excellegen®.”
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181204005336/en/